Malignancy Spectrum最新文献

{"title":"Effect of PD-1/PD-L1 immune checkpoint inhibitor in squamous and nonsquamous non-small cell lung cancer: A systematic review and meta-analysis","authors":"Zhenjie Dai,&nbsp;Jing Chen,&nbsp;Yong Wang","doi":"10.1002/msp2.40","DOIUrl":"https://doi.org/10.1002/msp2.40","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The effects of programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors (ICIs) in patients with squamous and nonsquamous non-small cell lung cancer (NSCLC) remain controversial. We conducted a meta-analysis to summarize the existing evidence on this topic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched PubMed, Medline, and Embase for studies published before December 1, 2022, comparing PD-1/PD-L1 ICIs with docetaxel in squamous and nonsquamous NSCLC patients in any language. The different hazard ratio (HR) values for overall survival (OS) and progression-free survival (PFS) were calculated in this study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of seven studies were identified. In a summary analysis of all studies, the HR values of OS in patients with nonsquamous and squamous NSCLC were 0.73, 95% confidence interval (CI): 0.67–0.79 and 0.70, 95% CI: 0.62–0.79, respectively. In patients with PD-L1 expression levels of 1% or higher, the HR values of OS in nonsquamous and squamous NSCLC patients were 0.60, 95% CI: 0.49–0.74 and 0.72, 95% CI: 0.54–0.96, respectively. The HR values of OS in nonsquamous and squamous NSCLC patients with PD-L1 expression levels of 5% or higher were 0.46, 95% CI: 0.35–0.59 and 0.55, 95% CI: 0.39–0.79, respectively. In nonsquamous and squamous NSCLC patients with PD-L1 expression levels of 10% or higher, the HR values of OS were 0.42, 95% CI: 0.32–0.54, and 0.53, 95% CI: 0.36–0.78, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The meta-analysis demonstrated possible evidence that there was different efficacy of PD-1/PD-L1 ICIs on OS in squamous and nonsquamous NSCLC patients with different PD-L1 expression levels. Subgroup analysis showed that there was a greater OS benefit in patients with nonsquamous NSCLC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 3","pages":"197-204"},"PeriodicalIF":0.0,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.40","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142276590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent response to combination treatment of pemigatinib and chemotherapy in a patient with advanced gastric cancer: A case report","authors":"Jing Wu,&nbsp;Yuehong Cui,&nbsp;Shan Yu","doi":"10.1002/msp2.39","DOIUrl":"10.1002/msp2.39","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to report the treatment and outcomes of a patient with advanced gastric cancer (GC) using a combination of a targeted molecular therapy and chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and methods</h3>\u0000 \u0000 <p>A 40-year-old woman presented with abdominal metastatic nodules and peritoneal effusion. Biopsy and cytology identified signet ring cell carcinoma. Ten months after the onset of initial symptoms, gastroscopy confirmed signet ring cell carcinoma of the gastric body. Genetic testing revealed amplification of the fibroblast growth factor receptor (<i>FGFR</i>) gene. Consequently, the patient received FGFR inhibitor pemigatinib in addition to a chemotherapy regimen of albumin paclitaxel plus 5-fluorouracil.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the treatment, the patient experienced recurrent liver function abnormalities and intestinal obstruction, which were managed with symptom-specific medications and supportive therapies. The combined treatment regimen resulted in a progression-free survival (PFS) period of ten months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The integration of FGFR inhibitor pemigatinib with standard chemotherapy showed promising results in prolonging PFS in a patient with advanced GC characterized by <i>FGFR</i> gene amplification, despite the occurrence of manageable side effects.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 3","pages":"217-222"},"PeriodicalIF":0.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.39","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141805878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hotspots and frontiers in cervical cancer research: A bibliometric and visualization analysis from 2013 to 2022","authors":"Haomeng Zhang,&nbsp;Yunkai Xie,&nbsp;Shuning Chen,&nbsp;Chunjie Piao,&nbsp;Chu Zhang,&nbsp;Weimin Kong","doi":"10.1002/msp2.28","DOIUrl":"10.1002/msp2.28","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cervical cancer is a highly aggressive cancer that seriously affects the physical and mental health and quality of life of women, especially for women in developing countries. Therefore, cervical cancer has always been the focus of research, and in recent years, various studies on cervical cancer have emerged one after another.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Our study aimed to illustrate the development trends in cervical cancer research in China from 2013 to 2022 and compare the findings with studies in other parts of the world during the same period by using bibliometric analysis and the Science Citation Index Expanded. Literature data were analyzed and visualized by using CiteSpace and VOSviewer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The results show that the number of articles on cervical cancer has increased in recent years, among which articles on the pathogenesis and epidemiological characteristics of cervical cancer account for the majority. The research in China has developed rapidly in recent years, but there is still a certain gap compared with other developed countries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Bibliometric and visualization analyses offer a unique and objective perspective in the field of cervical cancer and may assist scholars in identifying new research directions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 3","pages":"175-188"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.28","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141832066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forty years of practice against gastric cancer in Linqu County, a high-risk area of gastric cancer in China","authors":"Kai-Feng Pan,&nbsp;Wen-Qing Li,&nbsp;Wei-Cheng You","doi":"10.1002/msp2.38","DOIUrl":"10.1002/msp2.38","url":null,"abstract":"<p>Gastric cancer (GC) is a global public health burden, with nearly one million new cases diagnosed each year worldwide. To investigate the risk factors and the prevention strategies for GC, in the past 40 years, a series of epidemiological studies have been carried out in Linqu County, Shandong Province, a high-risk area of GC in China. Here, we briefly review the major efforts of 40-year practices against GC in Linqu County, particularly highlighting a case-control study to identify GC risk factors, a cohort study to determine the associations between the risk factors and the progression of gastric lesions, and an intervention trial to prevent GC development.</p>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 3","pages":"141-146"},"PeriodicalIF":0.0,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.38","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141665579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Keep pace with digital innovations","authors":"Zi Wang,&nbsp;Wenfeng Tu,&nbsp;Yi Yang","doi":"10.1002/msp2.31","DOIUrl":"10.1002/msp2.31","url":null,"abstract":"&lt;p&gt;At the beginning of 2024, the artificial intelligence company OpenAI introduced Sora, an innovative artificial intelligence digital product, marking a new milestone in digital technology. In this digital era, our Editorial Office is concerned with how to harness the innovations in scientific communication and translate them into potential advantages for scientific journals to support the development of &lt;i&gt;Malignancy Spectrum&lt;/i&gt; (MSP). MSP boasts significant strengths in timely publication, academic credibility, professional focus, and international engagement. Presently, new digital formats continue to emerge, infusing scientific communication with renewed vigor. These advancements have the potential to greatly enhance the influence of MSP in the scientific communication landscape.&lt;/p&gt;&lt;p&gt;Scientific communication is a broad concept that arises from the interaction between science and society, encompassing the dissemination of scientific information, popularization of scientific knowledge, advocacy for scientific methods, and cultivation of scientific culture. Scientific journals serve as a crucial social link for addressing scientific issues: they represent one of the primary channels for scientific communication, conveying the latest research findings and theories. Moreover, scientific journals play a pivotal role in maintaining the integrity and reliability of scientific communication methodologies. They also serve as essential conduits for disseminating scientific knowledge and improving scientific literacy between the academic community and the general public. The principles and guidelines of scientific communication are deeply rooted in the operational practices of scientific journals. The advancement of scientific journals contributes to the evolution of scientific communication principles, highlighting an intimate interconnection between the two. Therefore, innovation in scientific communication guides the evolution of scientific journals, while the digitization of scientific communication introduces new dynamics in their development.&lt;/p&gt;&lt;p&gt;With the rapid advancement of digital technology, the modes of scientific communication have evolved from traditional text and images to encompass multimedia and virtual technologies, thereby altering the delivery of scientific content. For instance, the progression of digital technology has introduced multimedia formats such as videos, audio, and animations, alongside virtual digital technologies like virtual reality (VR), augmented reality (AR), and mixed reality (MR). Artificial intelligence products such as ChatGPT and Sora facilitate diverse forms of scientific communication. This diversification not only offers novel tools and platforms for scientific communication but also significantly amplifies audience engagement, enabling immersive interaction. For instance, users can utilize Sora to construct digital environments, experience intricate scientific phenomena firsthand via VR technology, visu","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 4","pages":"223-224"},"PeriodicalIF":0.0,"publicationDate":"2024-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.31","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141273883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The necessary role of an efficient tumor immunotherapy by MHC II expression on amateur APCs","authors":"Jiaxin Zhong,&nbsp;Xiaorong Lin,&nbsp;Hai Hu","doi":"10.1002/msp2.29","DOIUrl":"https://doi.org/10.1002/msp2.29","url":null,"abstract":"<p>Antigen presentation, as the initial step in inducing the activation of T lymphocytes, plays a crucial role in antitumor response. Studies concentrating on major histocompatibility complex class II (MHC II) molecules and the activated CD4⁺ helper T (Th) cells have gained popularity in light of the past limited efficacy of MHC I-activated CD8⁺ T cells alone. In general, MHC II is canonically expressed by professional antigen-presenting cells (pAPCs), yet attempts to increase antigen presentation by dendritic cell (DC) activation have mostly been unsuccessful. In recent years, a number of studies have found that a variety of cells, including cancer cells, fibroblasts, vascular endothelial cells (VECs), and lymphoid stromal cells (LSCs), are considered amateur APCs (aAPCs) and can express MHC II molecules, which have piqued the interest of researchers. These groups vastly outnumber DCs or macrophages, and it has been confirmed that they also qualify as antigen-presenting complexes that are functionally related to conventional pAPCs. Herein, we will review current research regarding the antigen presentation process of MHC II, its advances in APC surfaces, especially for aAPCs, the special mechanisms of regulation of MHC II on aAPCs, and combination therapy targeting MHC II as a possible treatment strategy in cancer.</p>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 3","pages":"147-161"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.29","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142276592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Competing-risks model for predicting the prognosis of patients with regressive melanoma based on the SEER database","authors":"Chaodi Huang,&nbsp;Liying Huang,&nbsp;Jianguo Huang,&nbsp;Xinkai Zheng,&nbsp;Congjun Jiang,&nbsp;Kong Ching Tom,&nbsp;U. Tim Wu,&nbsp;WenHsien Ethan Huang,&nbsp;Yunfei Gao,&nbsp;Fangmin Situ,&nbsp;Hai Yu,&nbsp;Liehua Deng,&nbsp;Jun Lyu","doi":"10.1002/msp2.25","DOIUrl":"10.1002/msp2.25","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The relationship between the regression and prognosis of melanoma has been debated for years. When competing-risk events are present, using traditional survival analysis methods may induce bias in the identified prognostic factors that affect patients with regressive melanoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data on patients diagnosed with regressive melanoma were extracted from the Surveillance, Epidemiology, and End Results (SEER) database during 2000–2019. Cumulative incidence function and Gray's test were used for the univariate analysis, and the Cox proportional-hazards model and the Fine–Gray model were used for the multivariate analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1442 eligible patients were diagnosed with regressive melanoma, including 529 patients who died: 109 from regressive melanoma and 420 from other causes. The multivariate analysis using the Fine–Gray model revealed that SEER stage, surgery status, and marital status were important factors that affected the prognosis of regressive melanoma. Due to the existence of competing-risk events, the Cox model may have induced biases in estimating the effect values, and the competing-risks model was more advantageous in the analysis of multiple-endpoint clinical survival data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The findings of this study may help clinicians to better understand regressive melanoma and provide reference data for clinical decisions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 2","pages":"123-135"},"PeriodicalIF":0.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.25","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140732012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicle-based biomarker in head and neck cancer: prospects and challenges","authors":"Linlin Wang,&nbsp;Ling Li,&nbsp;Guiquan Zhu","doi":"10.1002/msp2.24","DOIUrl":"10.1002/msp2.24","url":null,"abstract":"<p>Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common malignancy worldwide. However, very few established diagnostic biomarkers for HNSCC have been universally applied in clinical practice. Recently, much attention has been paid to extracellular vesicles (EVs) regarding their roles as cancer biomarkers because EVs carry plentiful cargoes, including lipids, proteins, nucleic acids, and metabolites. In HNSCC, several molecules carried by EVs, which are derived from peripheral blood and saliva, have been implicated to be effective in cancer detection, staging, treatment planning, response monitoring, and prognosis prediction. Although several EV molecules have been identified to be significantly correlated with a set of clinical-pathological parameters of HNSCC, several key limitations need to be resolved before the clinical application of EVs as carriers of biomarkers in HNSCC. In this review, we discuss current knowledge in the literature regarding EV-based biomarkers in HNSCC, emphasizing current limitations of their clinical applications.</p>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 2","pages":"75-90"},"PeriodicalIF":0.0,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.24","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140735259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A broad scope, a broad readership, and a broad purpose","authors":"Qimin Zhan,&nbsp;Weimin Li,&nbsp;Wei Fu,&nbsp;Conor C. Lynch","doi":"10.1002/msp2.26","DOIUrl":"10.1002/msp2.26","url":null,"abstract":"<p>The long battle with cancer began centuries ago and despite many victories, the overall incidence continues to rise and it sometimes feels like that we are losing the war. The high rates and mortality of cancer have brought an increasing burden to society and so defeating the disease remains an urgent and unmet clinical need. In recent years, there has been a profound development of new knowledge and technologies that are widely employed in cancer research across multiple disciplines and even moreso, across the world. In modern times, it is hard to keep up with these breakthroughs, especially when they occur in varying regions. To address this, we are delighted to announce the launch of <i>Malignancy Spectrum</i> (MSP) in a bid to bring global advances in these disciplines together in one place.</p><p>MSP is an international open-access journal that intends to publish cutting-edge research in cancer biology and translational sciences that should be beneficial to the field of cancer research and clinical practice. The mission of MSP is to influence global cancer research and make contributions to an understanding of cancer biology and the development of novel therapeutic approaches by publishing peer-reviewed original research and thought-provoking reviews that accelerate the conversion application from bench-side to bed-side.</p><p>The content published in MSP will reach a broad range of scientists and clinicians across the field of cancer research. MSP publishes research articles in three categories: fundamental or translational research; clinical trials or epidemic cohorts; and novel biomedical technologies that would promote the development of cancer research.</p><p>We encourage submissions presenting innovative findings that create new directions in the research of cancer biology, as well as investigations that enrich our understanding of cancer prevention, clinical diagnosis, and treatment. This includes, but is not limited to, fundamental and translational work, clinical trials in all areas of cancer including studies in cancer genomics and tumor biomarkers, and developments in therapeutic approaches that contribute to prevention, diagnostics, treatment, and healthcare. We will also publish reviews that cover recent literature and author's options in such exciting fields.</p><p>MSP is dedicated to building a bridge and applying a platform for communications between scientists, clinicians, and readers, including nonexperts who are interested in the field of oncology research. We are eager to collaborate with authors and reviewers to produce the best clinical and translational advances. MSP's professional in-house scientific editors work closely with authors, reviewers, and the journal's editorial board to ensure an efficient editorial process, fair and robust peer review, and rapid dissemination and communication of your research.</p><p>We highly appreciate your support in MSP and wish to work together with you to build a wonderful academ","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.26","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140743742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute coronary syndrome in a patient with gastric cancer treated by immune checkpoint inhibitor: A case report","authors":"Bin Guan,&nbsp;Lingyun Zhang,&nbsp;Shan Yu","doi":"10.1002/msp2.23","DOIUrl":"10.1002/msp2.23","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To highlight the incidence and management of acute coronary syndrome (ACS) in patients with gastric cancer undergoing immune checkpoint inhibitor (ICI) therapy, emphasizing the need for early detection and intervention in this high-risk population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and methods</h3>\u0000 \u0000 <p>We presented a case of a 71-year-old male patient with poorly differentiated adenocarcinoma of the gastric antrum, clinical stage cT4N2M0, phase III, with no prior history of chronic diseases or cardiovascular risk factors. The patient was treated with a combination of ICI therapy (sintilimab) and chemotherapy using the albumin-bound paclitaxel combined with S1 regimen. Following therapy, he developed symptoms and diagnostic findings consistent with ACS, which was managed with percutaneous coronary stenting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The patient's presentation with ACS during ICI therapy underscored the potential cardiovascular risks associated with cancer treatments, particularly in patients without traditional cardiovascular risk factors. Management involved collaboration between oncologists and cardiologists, leading to successful coronary stenting and continuation of antitumor therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ACS is a significant risk in patients with malignancies undergoing ICI therapy, even in those without prior cardiovascular disease. Early recognition and management of ACS in this context are crucial to enable the continuation of cancer treatment and improve patient outcomes. This case underscores the importance of interdisciplinary collaboration in managing complex patients with concurrent cancer and cardiovascular disease.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100882,"journal":{"name":"Malignancy Spectrum","volume":"1 2","pages":"136-140"},"PeriodicalIF":0.0,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/msp2.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140371372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}